Several studies have shown that controlling blood lipids can significantly reduce cardiovascular events. So how low should lipid levels be reduced? Is there a greater clinical benefit to lowering lipids further than existing lipid-lowering medications? What is the safety profile? This may be a question for many patients and even clinicians. This article provides a brief overview of the latest FOURIER clinical study. The landmark FOURIER study, published March 17 in The New England Journal of Medicine, included 27,564 patients from 49 countries from February 2013 to June 2015 in a 1:1 randomized controlled study of subjects at high cardiovascular risk. The study was a 1:1 randomized controlled study in which the treatment group was treated with the PCSK9 inhibitor Evolocumab and the control group was treated with placebo. The results of the study showed a 59% reduction in LDL-C (median level to 0.78 mmol/L) in the Evolocumab-treated group compared to the placebo group; in the cardiovascular outcome event reduction study, the primary endpoint (cardiovascular death, myocardial infarction, stroke, unstable angina or coronary remodeling) was reduced by 15% in the Evolocumab-treated group compared to the placebo group, and the secondary endpoint (cardiovascular death, myocardial infarction, stroke, unstable angina or coronary remodeling) was reduced by 15%. There was a 15% reduction in the incidence of secondary endpoint events (cardiovascular death, infarction and stroke) and a 20% reduction in the incidence of secondary endpoint events (cardiovascular death, infarction and stroke). Also, Evolocumab was safe and well tolerated in the study. Thus, for patients with known cardiovascular disease, a higher intensity and greater reduction in lipid levels with Evolocumab, a PCSK9 inhibitor, may further reduce cardiovascular events and provide greater clinical benefit; at the same time, the study also confirmed that reducing LDL-C to very low levels (0.78 mmol/L) remains safe. While the positive findings from FOURIER are certainly encouraging, there is still a long way to go for the widespread use of Evolocumab, a PCSK9 inhibitor, due to its price and indication. To date, statin lipid-lowering drugs remain the most well-studied cholesterol-lowering drugs with the best efficacy-price ratio. Patients at high cardiovascular risk should adhere to statin therapy and follow their doctor’s orders in the process of medication use, and should not stop medication on their own because they think their lipid levels are “normal. In addition, Chinese medicine is good at lowering lipid levels and improving lipid metabolism, and better clinical outcomes can be achieved by using Chinese medicine to intervene on the basis of modern lipid-lowering drugs.